ArticleAmerican journal of physiology. Endocrinology and metabolism2025
Enhanced quantification of α-cell suppression by hyperglycemia using a high-sensitivity glucagon assay.
Article in American journal of physiology. Endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Accurate measurement of glucagon concentrations in a variety of conditions is necessary for subsequent estimation of glucagon secretion. Glucagon arises in the α-cell as a product of proglucagon processing. Modern two-site immunoassays have overcome prior problems with glucagon measurement caused by cross-reactivity with other proglucagon-derived fragments. However, in response to hyperglycemia, glucagon concentrations can fall below the limit of quantification of commercial immunoassays. This has implications for the characterization of α-cell function in health, in prediabetes, and in type 2 diabetes. An increase in the sensitivity of glucagon measurement was achieved by ethanol precipitation and concentration of the sample before measurement. Concentrating the sample sixfold enabled a decrease in the level of quantitation from 1.7 to 0.3 pmol/L with acceptable precision. To establish whether this enhanced high-sensitivity glucagon assay enhances the characterization of α-cell function in health and disease, we then estimated glucagon secretion rate (GSR) in four subjects. We subsequently used the relationship of GSR to glucose concentrations to characterize the α-cell response to glucose and demonstrate improved characterization of α-cell dysfunction in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.